-
Barcelona hit seven in Racing Santander rout
-
US Fed raises rates to tackle 'too high' inflation, irking Trump
-
Amorim's Milan beaten by Benfica, Sunderland make dream European return
-
Man Utd misery mounts after League Cup collapse against Brighton
-
US stocks fall, dollar gains after Fed lifts interest rates
-
Turkey releases 106 protesters, jails more LGBTQ activists
-
Seahawks rule out Darnold for Sunday game at Arizona
-
US Fed raises rates to tackle 'too high' inflation in move sure to rile Trump
-
Mbappe explains Ceuta shirt stance after criticism
-
England were 'waiting for death' in World Cup semi-final defeat: Tuchel
-
Improving Atletico cruise to comfortable win over Osasuna
-
NFL star fined for displaying name of slain Palestinian girl
-
Candidate for UN chief calls for AI regulation akin to nuclear weapons
-
Witsel retires from internationals after 18-year Belgium career
-
O'Neill expects Celtic recovery after Old Firm misery
-
US Fed raises rates to battle inflation in move likely to rile Trump
-
Man City midfield trio backed to emulate Rodri and Silva
-
Fitzpatrick 'not comfortable' over Dubai golf finale
-
'We're losing control,' AI pioneer Yoshua Bengio tells AFP
-
Gaza apartment block collapse kills 21, including 12 children
-
WHO eyes 'encouraging' signs in DRCongo fight against Ebola
-
Gaza apartment block collapse leaves 21 dead
-
Liga boss criticises Real Madrid trio for Ceuta shirt incident
-
US House targets data centers as midterm backlash grows
-
WTA Finals moved to Charlotte from 2027
-
French ex-minister Dati goes on trial in Renault-Nissan corruption case
-
Almost 8,000 excess deaths in France's scorched summer: statistics
-
'Being Heumann' captures joy in fight for disability rights
-
Ex-president's lengthy war crimes sentence shocks Kosovo
-
Retired great Nadal to play in exhibition matches
-
US House faces test on sweeping Russia sanctions bill
-
IR-MED and Dice Technologies Announce collaboration to Evaluate and Advance Pressure-Injury Prevention Platform in Japan
-
British PM says to make 'difficult decisions' as inflation rises
-
Watts, Pitt, Cruz to light up Spain's top film festival
-
TotalEnergies pumps up controversy in France with cut-price gas
-
Sweden expels Iran embassy employee over anti-Jewish threats
-
Global fuel price demos: a round-up
-
Toogood Gold's Table Mountain Sits in the Shadow of a Nevada Gold Rush
-
Leverate Launches MCP for Traders to Connect AI Assistants With Trading Platforms
-
MEXC July–August Security Report: 38.66M USDT in Risk Funds Intercepted, Futures Insurance Fund Hits 792M USDT
-
MEXC Launches $1M "Discover Your Wall Street DNA" Campaign to Help Traders Find Their Market Fit
-
'Breathing toxin every day': Indonesians choked by haze feel helpless
-
Emporio Armani names Dario Vitale new creative director
-
Stocks edge higher ahead of US Fed rate call
-
Maresca defends VAR officials after Man City benefit from error
-
Philippines ex-leader Duterte makes first in-person ICC appearance
-
Courts jails LGBTQ activists as Turkey crackdown widens
-
2027 Formula One calendar includes Monaco sprint race
-
French court to hear Depardieu's appeal against rape trial order: sources
-
Palestinians are the real victims, Thunberg tells Ed Sheeran
BioEdge Research Labs Expands Independent Analytical Testing Program
US-based research peptide supplier broadens third-party analytical testing and per-batch Certificate of Analysis documentation across its research product line. All products are sold for laboratory research use only.
WILMINGTON, DE / ACCESS Newswire / September 4, 2026 / BioEdge Research Labs, a United States-based supplier of research peptides and reference materials, today announced an expansion of its independent analytical testing program. The expanded program broadens the analytical testing and batch-level documentation that accompany the company's research-use-only materials, reinforcing an approach built on verifiable, laboratory-grade documentation.
Independent analytical testing and verifiable records have become central to how laboratory and research customers evaluate research-grade materials. Rather than relying on a supplier's description alone, researchers increasingly expect documentation they can review and confirm for the specific material they receive. BioEdge's program is built around third-party analysis and a batch-specific Certificate of Analysis (COA) for every lot, giving researchers analytical records to review both before and after purchase.
Third-Party Analytical Testing
Under the expanded program, BioEdge research materials are analyzed by an independent third-party laboratory. Testing covers identity and purity by established analytical methods, including high-performance liquid chromatography (HPLC) for purity and mass spectrometry (MS) for identity confirmation, alongside contaminant screening. Reporting each result on a Certificate of Analysis tied to the specific batch allows a researcher to see the underlying analytical data, not only a summary figure.
A Certificate of Analysis for Every Lot
Each vial carries a lot number that corresponds to its own Certificate of Analysis, rather than a single certificate carried forward across multiple production runs. Because analytical results can vary from one batch to the next, per-lot documentation is what allows a researcher to match the record to the material actually in hand. Batch-specific COAs are made available on the company's product pages, and each lot number is intended to correspond to the documentation for that batch.
Documentation and Transparency
The expanded program reflects a broader emphasis on transparency in the research materials market. By centering the process on independent analysis and accessible, batch-level records, BioEdge aims to give qualified researchers a clear basis for evaluating identity, purity, and analytical documentation across the product line.
Research Use Only
All materials supplied by BioEdge Research Labs are sold strictly for laboratory research and in vitro use by qualified researchers and scientific professionals. They are not drugs, supplements, or medical products.
About BioEdge Research Labs
BioEdge Research Labs is a United States-based supplier of research peptides and reference materials serving laboratory and research customers. The company provides research-grade materials supported by independent third-party analytical testing and batch-specific Certificates of Analysis. Learn more at https://thebioedgeresearchlabs.com.
Media Contact
1842 Marketstone Avenue, Suite 410
Wilmington, DE 19801
(302) 757-0147
[email protected]
All products sold by BioEdge Research Labs are intended strictly for laboratory research and in vitro use by qualified researchers and scientific professionals. These products are not intended to diagnose, treat, cure, or prevent any disease, are not intended to affect the structure or any function of the body, and are not intended for human or veterinary use, consumption, or self-administration. They have not been evaluated or approved by the U.S. Food and Drug Administration for diagnostic, therapeutic, or preventative purposes. BioEdge Research Labs is a chemical supplier and is not a compounding pharmacy or outsourcing facility as defined under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. BioEdge Research Labs makes no therapeutic claims.
SOURCE: The BioEdge Research Labs
View the original press release on ACCESS Newswire
B.Torres--AT